This enhanced tumor inhibition was not observed with the anti–PD-1 agent alone (0.75 mg/kg or 0.5 mg/kg dose), with %TGI values of 55% and 57% and CR rates of 0 of 10 and 0 of 10, respectively. The gene discussed is PDCD1; the disease is neoplasm.